Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07477600 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

cfMSC Stem Cell Therapy Targeting COPD

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Mar 31, 2029 → Jun 30, 2029
See other at-risk trials from Shenzhen Geno-Immune Medical Institute

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Mar 10, 2026 to Jun 30, 2027v3 Show 6 more changesShow less
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Primary completion pushed from Mar 31, 2029 to Jun 30, 2029
    • Study completion moved earlier from Apr 30, 2030 to Dec 31, 2029
    • Secondary endpoints: 9 to 8
    • Study description expanded, about 66 words
    • Site details revised
  2. Study description expanded, about 5 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objectives are to evaluate the safety and efficacy of infusion of fully characterized clonally derived fetal mesenchymal stem cells (cfMSCs) for the control of severe symptoms associated with moderate to severe chronic obstructive pulmonary disease.
Trial Details
NCT Number NCT07477600
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 Chronic Obstructive Pulmonary Disease (COPD)
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov